Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       


Defensive Equity Portfolio, Series 50
Ticker Symbol: FBMSOX

30 Holdings (As of Day of Deposit)
Ticker Company Name Initial
Consumer Staples (46.66%)
MO Altria Group, Inc. 3.32% $46.59
KO The Coca-Cola Company 3.34% 54.49
STZ Constellation Brands, Inc. 3.31% 201.66
COST Costco Wholesale Corporation 3.36% 279.92
DEO Diageo Plc 3.29% 168.15
EL The Estee Lauder Companies Inc. 3.33% 202.56
MDLZ Mondelez International, Inc. 3.34% 54.51
MNST Monster Beverage Corporation 3.32% 57.19
NSRGY Nestle S.A. 3.35% 110.38
PEP PepsiCo, Inc. 3.35% 132.66
PG The Procter & Gamble Company 3.32% 119.42
TSN Tyson Foods, Inc. 3.36% 91.66
UL Unilever Plc 3.35% 61.71
WMT Walmart, Inc. 3.32% 111.91
Health Care (53.34%)
ABT Abbott Laboratories 3.36% 84.37
AMGN Amgen Inc. 3.34% 203.42
ANTM Anthem, Inc. 3.30% 261.06
CNC Centene Corporation 3.34% 45.55
CI Cigna Corporation 3.34% 155.78
EW Edwards Lifesciences Corporation 3.28% 216.67
LLY Eli Lilly and Company 3.31% 111.61
HCA HCA Healthcare, Inc. 3.32% 122.24
JNJ Johnson & Johnson 3.32% 131.27
MRK Merck & Co., Inc. 3.34% 86.72
NVO Novo Nordisk A/S 3.33% 52.70
SYK Stryker Corporation 3.31% 218.27
TMO Thermo Fisher Scientific Inc. 3.34% 278.17
UNH UnitedHealth Group Incorporated 3.38% 232.94
VRTX Vertex Pharmaceuticals Incorporated 3.37% 184.24
ZTS Zoetis Inc. 3.36% 126.64

* As of the close of business on 8/22/19.
Market values are for reference only and are not indicative of your individual cost basis.

Not FDIC Insured • Not Bank Guaranteed • May Lose Value

Portfolio Summary
Initial Date of Deposit 8/23/2019
Initial Public Offering Price $10.00 per Unit
Portfolio Ending Date 8/23/2021
Cash CUSIP 30311G683
Reinvestment CUSIP 30311G691
Fee Accounts Cash CUSIP 30311G709
Fee Accounts Reinvestment CUSIP 30311G717

Sales Charges (based on a $10 public offering price)
Standard Accounts
Transactional sales charges: Initial: 0.00%
  Deferred: 2.25%
Creation and Development Fee:   0.50%
Maximum Sales Charge:   2.75%

The deferred sales charge will be deducted in three monthly installments commencing 12/20/19.

When the public offering price is less than or equal to $10.00 per unit, there will be no initial sales charge. If the price exceeds $10.00 per unit, you will pay an initial sales charge.

Fee/Wrap Accounts
Maximum Sales Charge: 0.50%

The maximum sales charge for investors in fee accounts consists of the creation and development fee. Investors in fee accounts are not assessed any transactional sales charges. Standard accounts sales charges apply to units purchased as an ineligible asset.

The creation and development fee is a charge of $.050 per unit collected at the end of the initial offering period. If the price you pay exceeds $10.00 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than $10.00 per unit, the creation and development fee will exceed 0.50%.

In addition to the sales charges listed, UITs are subject to annual operating expenses and organization costs.

You should consider the portfolio's investment objective, risks, and charges and expenses carefully before investing. Contact your financial advisor or call First Trust Portfolios L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the portfolio. Read it carefully before you invest.

Risk Considerations
An investment in this unmanaged unit investment trust should be made with an understanding of the risks involved with owning common stocks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

You should be aware that the portfolio is concentrated in stocks in both the consumer products and health care sectors which involves additional risks, including limited diversification. The companies engaged in the consumer products industry are subject to global competition, changing government regulations and trade policies, currency fluctuations, and the financial and political risks inherent in producing products for foreign markets. The companies engaged in the health care sector are subject to fierce competition, high research and development costs, governmental regulations, loss of patent protection, and changing consumer spending trends.

An investment in a portfolio containing equity securities of foreign issuers is subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting foreign issuers.

As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cyber security.

This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

Fund Cusip Information
30311G683 (Cash)
30311G691 (Reinvest)
30311G709 (Cash-Fee)
30311G717 (Reinvest-Fee)
Printer Friendly Page Printer Friendly Page
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial advisors are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA.
First Trust Advisors L.P.
Home |  Important Legal Information |  Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2019 All rights reserved.